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Abstract
Introduction: The transcription factor Fli1 is implicated in the pathogenesis of systemic lupus erythematosus (SLE).
Recently, a GAn polymorphic microsatellite was characterized in the mouse Fli1 promoter that modulates promoter
activity and is truncated in two lupus mouse models compared to non-autoimmune prone mice. In this work, we
characterize a homologous GAn microsatellite in the human Fli1 promoter. The purpose of this study is to
determine the effect of the microsatellite length on Fli1 promoter activity in vitro and to determine if the length of
the GAn microsatellite is associated with SLE and/or specific disease characteristics.
Methods: Constructs with variable lengths of the GAn microsatellite in the Fli1 promoter were generated and
analyzed in promoter/reporter (P/R) assays in a human T cell line. Using three SLE patient cohorts and matched
controls, microsatellite length was measured and association with the presence of disease and the occurrence of
specific disease manifestations was assessed.
Results: P/R assays demonstrated that the presence of a shorter microsatellite resulted in higher Fli1 promoter
activity. A significant association was observed in the lupus cohort SLE in Gullah Health (SLEIGH) between the GA26
base pair allele and absence of nephritis.
Conclusions: This study demonstrates that a GAn microsatellite in the human Fli1 promoter is highly polymorphic.
The length of the microsatellite is inversely correlated to Fli1 promoter activity in a human T cell line. Although no
association between microsatellite length and lupus was observed, an association between a specific microsatellite
length and patients without nephritis in the SLEIGH cohort was observed.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic
autoimmune disease characterized by the production of
autoantibodies, formation of immune complexes and
subsequent deposition in target tissues with resultant
local inflammation and organ damage [1]. Nearly every
organ system can be involved in lupus with the most
prominent being the kidneys, joints, skin and brain [1].
The major determinant of morbidity and mortality is
renal involvement, although infection and cardiovascular
disease are leading causes of death. The American Col-
lege of Rheumatology outlines the most common dis-
ease outcomes of SLE in the 1997 revised classification
criteria including arthritis, serositis, nephritis, immune-
mediated cytopenias, and lupus-specific autoantibody
positivity. Commonly, the course of disease will include
periods of remission and flares and the disease presenta-
tion is heterogeneous among patients making SLE a dif-
ficult disease to characterize, diagnose, and study.
Similar to most autoimmune diseases, lupus is believed
to result from an environmental event triggering disease
in a genetically susceptible individual.
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Increasing evidence suggests that dysregulation of the
transcription factor Fli1 contributes to the pathogenesis
of lupus. Fli1 is a member of the Ets family of transcrip-
tion factors and is preferentially expressed in endothelial
and hematopoietic cell lineages. Levels of expression are
linked to the pathogenesis of lupus. During lymphoid
development, Fli1 is highly expressed in immune cells
including mature B cells, pre-T cells, and resting,
mature T cells [2]. Over-expression of Fli1 in peripheral
blood mononuclear cells (PBMCs) in lupus patients is
correlated with disease activity [3]. Fli1 is over-expressed
in several lupus mouse models including T cells of
NZB/NZW f1 mice and spleen of MRL/lpr mice [3,4].
Transgenic global over-expression of Fli1 in healthy,
non-autoimmune prone mice results in a lupus-like phe-
notype with the presence of autoreactive lymphocytes,
autoantibodies and the development of immune com-
plex mediated kidney disease [5]. Conversely, reduction
of Fli1 levels by 50% in MRL/lpr and NZM2410 lupus-
prone mice improved the disease phenotypes in these
models by decreasing autoantibody production and kid-
ney disease and significantly prolonging survival [4,6].
This evidence demonstrates that expression levels of
Fli1 in lupus affect disease phenotype.
We demonstrated previously that a polymorphic
microsatellite consisting of GA repeats within the proxi-
mal promoter of the mouse Fli1 gene is shorter in the
MRL/lpr and NZM2410 lupus mouse models compared
to non-autoimmune prone BALB/c and C57BL/6 mice
[7]. Promoter/reporter (P/R) assays demonstrated that
in vitro activity of the mouse Fli1 promoter in a T cell
line was inversely correlated with microsatellite length.
The murine and human Fli1 promoters are highly homo-
logous with 88% homology in the proximal promoter
region, including the GA microsatellite [8]. Together,
these studies suggested that a shorter microsatellite in
the Fli1 promoter may contribute to over-expression of
Fli1 and to the pathogenesis of lupus. Using clinical data
and genomic DNA specimens from SLE patients and
controls, we demonstrate that the human microsatellite
shows a similar inverse correlation between length and
promoter activity in a human T cell line and that a
microsatellite length of GA26 is significantly more preva-
lent in SLE patients without nephritis and tended to be
more prevalent in SLE patients with serositis.
Materials and methods
Plasmid constructs
The promoter/reporter (P/R) constructs containing the
-502 to -37 region of the human Fli1 gene were gener-
ated from genomic DNA isolated from control subjects
in the Carolina Lupus Study as described previously [8].
The -502/-37 P/R constructs analyzed were identical
except for the difference in microsatellite lengths; 28,
24, 16 or 13 GA repeats. Two clones for each of the
microsatellite lengths were generated and tested. All
constructs were confirmed by direct sequencing.
Transfections
pGL3 hFli1-502/-37 P/R constructs were transfected
into the Jurkat human T cell line using Fugene (Pierce,
Rockford, IL USA) following the manufacturer’s direc-
tions. A Renilla luciferase construct was co-transfected
to normalize for transfection efficiency. Cells were har-
vested 24 hours after transfection and cell lysates were
analyzed for luciferase expression using the dual lucifer-
ase detection kit (Promega, Madison, WI USA) and
quantified using a luminometer. Promoter activity as a
measure of luciferase expression was compared to the
pGL3 Basic empty vector. Transfections were performed
at least three times in duplicate with two different
clones and averaged.
Cells
The Jurkat human T cell line was maintained in RPMI
1640 with 10% fetal bovine serum and antibiotics at
37°C and 5% humidity. Cells were passaged the day
prior to transfection.
Microsatellite fragment length measurements
The microsatellite containing region of the Fli1 proximal
promoter was amplified from genomic DNA from sub-
jects in the Carolina Lupus study (CLU), SLE in Gullah
Health study (SLEIGH) and the MUSC Lupus Clinic
study (Clinic) using the following primers: upstream pri-
mer, hGA2Up, 5’-/56-FAM/ATGTGTCTGGGCATCTC-
3’, contains a FAM fluorescent tag; and downstream pri-
mer, GADn, 5’-GCTAATTTTGGGAAGTGACT-3’. The
amplified, FAM-tagged PCR products were sent to the
DNA Facility at Iowa State University (Ames, IA, USA)
for high throughput genotyping analysis using the
Applied Biosystems 3100 Genetic Analyzer (Carlsbad,
CA, USA) and size marker. Several samples, including
those that were used to generate the P/R constructs,
were run across multiple plates to ensure consistent
amplification and sizing across plates and over half of the
samples were run twice. The raw sizing data were visually
analyzed for peak quality followed by analysis and bin-
ning using the GeneMapper software (Applied Biosys-
tems, Carlsbad, CA, USA). Direct sequencing of 32 of the
amplified products of various lengths demonstrated that
the differences in amplified product sizes were due to the
length of the microsatellite and not to other sequence
changes.
Subjects
This study utilized subject data from three lupus
cohorts. Genomic DNA was isolated from peripheral
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blood samples obtained from the study cohorts taken
upon receiving informed consent and in compliance
with the Institutional Review Board for Human Studies.
All aspects of this study were conducted according to
the Helsinki Declaration. The Carolina Lupus (CLU)
cohort is a case-control study investigating genetic and
environmental factors predisposing individuals to SLE
[9]. Patients enrolled in the CLU study were recruited
through university and community rheumatology in
eastern North Carolina and South Carolina. Patients
met at least 4 of the 11 revised American College of
Rheumatology classification criteria for SLE [10,11]. All
patients were diagnosed with SLE between 1 January
1995 and 1 July 1999 and were enrolled in the CLU
study within one year of diagnosis. Matched control
subjects were recruited from state driver’s license regis-
tries. At the time of enrollment, blood samples were
taken from the study subjects for the extraction of geno-
mic DNA.
The Systemic Lupus Erythematosus in Gullah Health
(SLEIGH) study includes African American lupus
patients and controls living on the Sea Islands of the
South Carolina and Georgia coasts [12]. SLEIGH sub-
jects represent a unique genetic group with a low per-
cent admixture of non-African genes. Subjects enrolled
in the SLEIGH study were self-identified as a member
of the African American Gullah community with no
known ancestors that were not of Gullah lineage.
Patients in SLEIGH met at least 4 of the 11 American
College of Rheumatology classification criteria for SLE
[10,11]. Patients were identified as multiplex if the diag-
nosis of SLE could be documented in one or more
family members. Population controls in SLEIGH used
for our analyses had no known family history of SLE or
other autoimmune disease and were matched on age
and gender to patient cases. Blood samples were taken
from the study subjects at the time of enrollment for
extraction of genomic DNA.
Caucasian and African American lupus patients from
the MUSC clinic that met 4 of the 11 American College
of Rheumatology classification criteria for SLE were
included for data collection. Blood samples were taken
for extraction of genomic DNA.
The clinic patients were included with the CLU study
for analyses. Separate analyses were performed on the
Caucasian and African American populations in order
to avoid possible confounders due to population stratifi-
cation. Initial analyses for the SLEIGH study data con-
sidered only patients not from multiplex families.
Additional analyses were performed on the SLEIGH
study data to include one multiplex patient chosen at
random from each multiplex family. Within each cohort,
three statistical testing approaches were considered.
Statistics
P/R assay data were analyzed by the Student’s t-test to
identify statistically significant differences. To begin ana-
lyses of the patient cohort data, hypothesis-generating
genotype tests were considered by dichotomizing into
short/long alleles and using 2-df Fisher’s exact tests (or
chi-squared tests where the counts of genotypes were
above five for each possible genotype) to test for asso-
ciation with disease between cases and controls or indi-
vidual disease characteristics within cases. Next, average
allele length was compared between cases and controls
using a two-sample t-test. Lastly, due to the large num-
ber of alleles observed, the CLUMP program was used
to compare each allele to all the other possible alleles.
The CLUMP program, described by Sham and Curtis
[13], allows testing each allele frequency against all
other allele frequencies, using a chi-squared test statistic.
Statistical analyses were performed separately on
patients from the SLEIGH study while patients in the
CLU and MUSC clinic cohorts were analyzed together.
Results
A GAn dinucleotide repeat in the proximal promoter of
the human Fli1 gene modulates in vitro promoter activity
in T cells
A polymorphic GAn dinucleotide microsatellite is pre-
sent in the proximal region of the human Fli1 promoter
271 base pairs upstream (-271) from the start site of
translation (Figure 1A, B). The location of this GAn
repeat is homologous to the polymorphic microsatellite
we recently analyzed in the mouse Fli1 promoter [7]. In
our previous study, deletion analyses of the human Fli1
promoter demonstrated that the microsatellite is not
required for full promoter activity in a T cell line [8].
However, the microsatellite was demonstrated to modu-
late the activity of the mouse promoter in T cells such
that the shorter the microsatellite the greater the pro-
moter activity [7].
To determine if there is a similar inverse correlation
between microsatellite length and promoter activity
with the human Fli1 promoter, P/R constructs contain-
ing microsatellites of 28, 24, 16, and 13 GA repeats
were transfected into the Jurkat human T cell line.
The pGL3 construct containing 13 GA (GA13) repeats
resulted in the highest level of Fli1 promoter activity
(Figure 1C). Promoter activity decreased as microsatel-
lite length increased with a statistically significant dif-
ference between the longest (GA28) and the shortest
(GA13) alleles (P < 0.001). This demonstrates that rela-
tive Fli1 promoter activity is inversely correlated with
the number of GA repeats in this human T cell line
similar to our previous study of the mouse Fli1
promoter [7].
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Distribution of microsatellite length in patients and
control subjects
In a previous study, expression of the Fli1 gene was
shown to be elevated in T cells from SLE patients com-
pared to unaffected control subjects [3]. Based on our
results demonstrating that the length of the microsatel-
lite is inversely correlated to Fli1 promoter activity and
that a shorter microsatellite is present in lupus-prone
mouse strains [7], we sought to determine whether the
length of the microsatellite is associated with SLE. The
microsatellite-containing region of the Fli1 promoter
was amplified and length measured in the Carolina
Lupus (CLU) study cohort, MUSC Lupus Clinic (Clinic)
study cohort and the SLEIGH study cohort. Demo-
graphics are presented in Table 1. The CLU and Clinic
cohorts were analyzed together and include 197 SLE
patients and 162 unaffected controls. The SLEIGH
cohort includes 154 patients and 97 unaffected controls
and for statistical analyses, the cohort data was divided
into two groups that either excluded multiplex families
or included one randomly selected patient from each
multiplex family.
Interestingly, following genotyping of these cohorts we
observed over 20 different alleles with a range of GA
repeats from 13 to 39 within these populations, indicat-
ing that this microsatellite is highly polymorphic in
humans. Allele distributions for each cohort are pre-
sented in Figure 2. Due to the large number of alleles,
the subjects were grouped into short and long alleles for
statistical analyses to determine if a shorter GA
Figure 1 A GAn microsatellite in the hFli1 promoter modulates activity in a human T cell line. A. Construct showing the location of distal
and proximal promoters, transcription start sites (arrows) and GA microsatellite (white box) in the Fli1 promoter. Numbering is relative to the +1
translation start site. B. Sequence of the human -502/-37 region is aligned with the equivalent -505/-37 region from mouse. The GA
microsatellite is in bold and primer sites used to amplify the microsatellite-containing region in human genomic DNA samples are underlined.
C. The -502 to -37 region of the human Fli1 promoter shown in B with different lengths of the GAn microsatellite was cloned from genomic
DNA samples of unaffected controls in the CLU study into the pGL3 Basic reporter vector. Constructs were transfected into Jurkat T cells and
assayed for promoter activity. Expression is presented relative to the pGL3 Basic empty vector, which was set to 1. Results are an average of
three independent transfections performed with two independently derived clones. *P < 0.005.
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microsatellite is associated with disease. Next, we com-
pared average microsatellite length between cases and
controls. No association was observed with either of
these analyses (data not shown).
We performed additional analyses to explore other
phenotype-genotype associations that were not initially
hypothesized, specifically the possibility that a particular
length may be associated with disease or a disease phe-
notype. Analyses of length in cases and controls in the
CLU cohort were separated into Caucasians (Figure 2A)
and African Americans due to concerns of population
stratification (Figure 2B). In general, the distribution of
alleles was similar in cases and controls. These results
indicate no significant differences in the overall
Table 1 Demographics of the study cohorts
Controls Patients
Total Numbers Age Range (Median Age) Total Numbers Age Range (Median Age)
CLU/MUSC Clinic Caucasians 110 18-75 (39) 62 18-51 (36)
CLU/MUSC Clinic African Americans 52 16-61 (33) 135 15-54 (37)
SLEIGH Without multiplex patients 97 11-74 (42) 123 10-69 (37)
SLEIGH With multiplex patients 97 11-74 (42) 154 10-70 (39)
The number of patients and controls and the median age ranges for the Carolina Lupus (CLU) study, Medical University of South Carolina (MUSC) clinic, and
System Lupus Erythematosus in Gullah Health (SLEIGH) study participants.
Figure 2 Distribution of the GAn microsatellite allele in patient and control subjects of the CLU and SLEIGH cohorts. A. CLU Caucasian
subjects. B. CLU African American subjects. C. African American patient population of the CLU cohort divided with respect to serositis
occurrence. D. SLEIGH subjects excluding multiplex patients (not shown on graph is one patient with an allele of 267 base pairs). E. SLEIGH
subjects including multiplex patients (not shown on graph is one patient with an allele of 267 base pairs). F. SLEIGH patient population divided
with respect to nephritis occurrence. *P < 0.05. All n values are representative of the number of patients, each patient having two alleles.
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distribution of microsatellite length between SLE
patients and unaffected controls in the CLU cohort
regardless of ethnicity. The same analyses were per-
formed with the SLEIGH cohort data. As in the CLU
cohort, the overall distribution was similar between
cases and controls whether the multiplex patients were
excluded (Figure 2D) or included (Figure 2E). These
results demonstrate no significant differences in the
overall distribution of microsatellite length between SLE
patients and unaffected controls in the SLEIGH cohort
regardless of inclusion of multiplex patients.
Assessment of microsatellite length and lupus disease
characteristics
To determine whether microsatellite length is associated
with specific disease characteristics, microsatellite length
was analyzed within the patient population of the
CLU and SLEIGH cohorts. Analyses conducted include
microsatellite length and occurrence of arthritis, serositis,
nephritis, immune-mediated cytopenias, and lupus-
specific autoantibody positivity. These disease character-
istics were defined using the 1997 revised American
College of Rheumatology SLE classification criteria [11].
The disease characteristic could have occurred at any
point in the patient’s history, however, must be attributa-
ble to lupus. As with allele distribution analysis, no signif-
icant associations were observed in analyses of short and
long alleles or average allele length with disease pheno-
types (data not shown).
We then analyzed the occurrence of specific allele
lengths with disease phenotypes. No significant associa-
tions were observed between microsatellite length and
arthritis, cytopenias, or lupus-specific autoantibody posi-
tivity in the CLU Caucasian, CLU African American or
SLEIGH populations (data not shown). Analyses of allele
length with nephritis in the SLEIGH cohort, excluding
multiplex patients, identified the 241 bp allele (GA26) as
being more prevalent in patients that did not develop
nephritis (Figure 2F). This difference was statistically
significant after adjusting for multiple comparisons (P <
0.05) (Table 2). These results suggest that the 241 base
pair allele may be protective against the development of
nephritis in SLE patients in the SLEIGH population.
The 239 bp (GA25) and 241 bp (GA26) alleles were
more prevalent in patients with serositis compared to
patients without serositis in the African American CLU
patients (Figure 2C and Table 2). Similarly, as shown in
the results summary in Table 2 the 239 bp (GA25) allele
was more prevalent in patients with serositis in the
SLEIGH cohort. However, these differences did not
remain statistically significant after adjusting for multi-
ple comparisons. We then combined the SLEIGH
cohort, which is entirely African American, and the
CLU African American populations to determine
whether increasing our sample size would result in sig-
nificant differences. Although the 239 bp (GA25) allele
length remained more prevalent when combining the
two populations, statistical significance was not obtained
(data not shown).
Discussion
We previously demonstrated that a polymorphic GAn
microsatellite in the mouse Fli1 promoter modulates
promoter activity in a T cell line and is evolutionarily
conserved [7]. Although the GAn microsatellite in the
mouse and human promoters is not required for pro-
moter activity in vitro [7,8], varying the length of the
microsatellite in the mouse promoter modulated promo-
ter activity in T cells with the length of the microsatel-
lite being inversely proportional to promoter activity [7].
Here we determined that the in vitro activity of the
human Fli1 promoter also decreased as the number of
GA repeats in the microsatellite increased (Figure 1C).
The inverse relationship between microsatellite length
and Fli1 promoter activity observed in mouse and
human suggests a possible functional role of the GAn
microsatellite in the regulation of Fli1 expression.
Microsatellites occur at high frequency in the protein
coding and non-coding regions of the human genome,
which has raised many questions about their function in
normal development and disease states [14]. Although
there are many examples in the literature of the ability of
microsatellites to affect expression of genes (including
EGFR, estrogen receptor b, Kv1.5, nucleolin, acetyl CoA
carboxylase, heme oxygenase I, matrix metalloproteinase
9, Cyr61, heat shock genes, collagen Ia2, and Pax6
[15-26]), the mechanisms involved are not entirely
understood. Microsatellites are thought to function pri-
marily by altering chromatin structure. Specifically, prop-
erties of GA microsatellites include the ability to adopt
Table 2 Summary of results
Alleles associated with patients CLU SLEIGH
Caucasian (n = 62) AA (n = 135) Without Multiplex (n = 123) With Multiplex (n = 154)
With Serositis none 239/241 239 239
Without Nephritis none none 241 (p < 0.05) 241
Summary of results for the Carolina Lupus (CLU) study African American (AA) and Caucasian participants and for the Systemic Lupus Erythematosus in Gullah
Health (SLEIGH) participants.
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H-form DNA and bind GAGA factor. The H-DNA con-
formation includes both single- and triple-stranded
regions that are DNase I-hypersensitive [27] and may
provide an open chromatin configuration that allows
binding of transcription factors to neighboring regulatory
elements [28,29]. GAGA factor is a protein identified in
Drosophila and its binding to GA-rich sequences in pro-
moters can repress or activate transcription through
effects on nucleosomes [30-33]. Recently, the vertebrate
homolog of GAGA factor, th-POK, was identified and
demonstrated to bind GA-rich sequences [34]. Addition-
ally, GA-rich sequences are thought to play a role as
enhancer-blocking or insulator elements [35]. The Fli1
GA microsatellite was demonstrated previously to be
sensitive to nuclease S1 digestion and shown to form
H-DNA in vitro [36,37]. Our in vitro experiments with
both the mouse and human promoters support a role of
the microsatellite in dampening promoter activity as
length increases but not in complete repression of activ-
ity. How this microsatellite functions in vivo remains to
be determined.
Previous results demonstrated that Fli1 expression is
increased in mouse models of lupus [3,4] and in T cells
of SLE patients [3] compared to unaffected controls.
Interestingly, globally decreasing Fli1 levels by 50% in
two different lupus mouse models resulted in signifi-
cantly improved disease, most notably improved nephri-
tis, accompanied by significantly prolonged survival
[4,6]. Furthermore, it was demonstrated that reducing
Fli1 levels by 50% in hematopoietic cells in a lupus
mouse model also resulted in improved disease and sur-
vival [38]. Together these studies demonstrated that
modulating Fli1 levels plays an important role in the
progression of lupus. Based on these observations and
our P/R results demonstrating that the length of the
microsatellite modulates Fli1 expression, we hypothe-
sized that a shorter microsatellite in the Fli1 promoter
may lead to over-expression of Fli1 and thus may be
associated with lupus or with specific disease pheno-
types such as nephritis. The association of microsatel-
lites with the occurrence of several diseases including
SLE, rheumatoid arthritis, lung fibrosis, epithelial ovar-
ian cancer, thyroid cancer, acute pancreatitis, breast
cancer, and multiple neurological diseases has been
reported [39-48].
We expected the microsatellite to be polymorphic in
the human population; however, we were surprised to
observe more than 20 different alleles spanning 13 to 39
GA repeats in the populations tested, including the
highly genetically related SLEIGH population. The
highly polymorphic nature of this microsatellite is inter-
esting and prompted multiple analyses to explore all
possible phenotype-genotype associations. Although
the GAn microsatellite length had an effect on Fli1
promoter activity in vitro, no association was identified
between microsatellite allele length and the occurrence
of SLE in the SLEIGH and CLU cohorts. The pathogen-
esis of SLE is complex and it is likely that the disease
results from alterations in the expression of multiple
target genes. Thus, Fli1 may contribute to the progres-
sion of disease but we believe it is more likely to be
associated with a specific disease characteristic.
To determine if GA microsatellite length is associated
with specific aspects of SLE we compared the presence
of lupus-specific characteristics with microsatellite
length. No association was observed between microsatel-
lite length and arthritis, cytopenia or lupus specific auto-
antibodies. To our knowledge, it is unknown whether
Fli1 plays a role in the development of arthritis or cyto-
penia in lupus, although it was demonstrated that redu-
cing Fli1 levels in a lupus mouse model had no effect
on total B cell or T cell numbers [4]. Therefore, it is not
unexpected that no association between the Fli1 micro-
satellite and arthritis or cytopenia was observed. Based
on results in lupus mouse models in which reducing
Fli1 levels resulted in decreased autoantibody levels
[4,6], we expected to observe an association of the Fli1
microsatellite with autoantibody production. However,
the effect of Fli1 on autoantibody levels appears to be
secondary to effects on B cell activation [4], which may
account for the apparent lack of association of the Fli1
microsatellite with autoantibodies in our study.
The 241 bp allele (GA26), was significantly associated
with SLE patients that did not have nephritis in the
SLEIGH cohort (Figure 2F and Table 2). Alleles of 239
and 241 bp, 25 and 26 GA repeats respectively, were
more prevalent, although not significantly, in African
American CLU patients with serositis (Figure 2C and
Table 2). In vitro constructs in this long size range (23
to 28 repeats) exhibited weaker activation of the Fli1
promoter in P/R assays (Figure 1C), suggesting that
lower Fli1 expression may be protective against nephritis
and contribute to serositis. In lupus mouse models in
which Fli1 levels were reduced globally or specifically in
hematopoietic cells, nephritis was improved [4,6,38].
Conversely, expression of Fli1 in mouse endothelial cells
controls vascular maturation and is required to maintain
vascular integrity [49]. We speculate that a reduction in
Fli1 promoter activity and, hence, expression may dis-
rupt endothelial cell function in lupus patients and con-
tribute to exaggerated serositis.
These findings support previous hypotheses that the
effects of Fli1 expression in different cell types are vari-
able and aberrant expression of Fli1 can contribute to
the development of disease. For example, in sclero-
derma, reduced expression of Fli1 in skin fibroblasts and
endothelial cells is implicated in the fibrotic and vascu-
lar components of the phenotype [49], while in lupus
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elevated expression of Fli1 in mononuclear cells is
thought to contribute to the disease phenotype [3]. It is
conceivable that the 241 bp allele representing a micro-
satellite of 26 GA repeats may delineate a threshold
length of the microsatellite. Individuals with a Fli1 GAn
microsatellite at or above the threshold may have lower
levels of Fli1 expression in their lymphocytes, which
would be protective against developing lupus nephritis
while individuals with a Fli1 GAn microsatellite at or
above the threshold may have lower expression levels of
Fli1 in their endothelial cells, which may contribute to
serositis. However, we tested all dichotomies of short/
long alleles and didn’t observe significant differences,
suggesting that increased and decreased expression of
Fli1 may be modulated by a specific length of the GA
microsatellite.
Conclusions
In this work, we characterized a highly polymorphic
microsatellite of GA repeats in the human Fli1 promoter.
Variable lengths of the GAn microsatellite modulated Fli1
promoter activity in vitro in a human T cell line such that
the shorter the microsatellite the greater the promoter
activity. Although aberrant expression of Fli1 in PBMCs
was observed previously in SLE patients [3], specific asso-
ciation between microsatellite length and SLE was not
observed in this study. However, the GA26 microsatellite
length was specifically associated with patients that did
not have nephritis and tended to be more prevalent in
African American patients with serositis. Due to the highly
polymorphic nature of this microsatellite, a greater num-
ber of additional subjects in these cohorts would be
required to increase the statistical power in order to deter-
mine significant associations for each allele and/or geno-
type, especially within the shortest and longest alleles,
which appear to be relatively rare. The expression of Fli1
in different cell types may mediate pathological effects that
contribute to the multifaceted role of Fli1 in SLE. A more
precise understanding of how this microsatellite functions
to modulate Fli1 expression in different cell types would
be beneficial in determining whether this microsatellite
may serve as therapeutic marker in lupus. Future studies
are aimed at determining whether the length of the Fli1
GAn microsatellite correlates with Fli1 expression levels in
primary human cells and how the GA microsatellite pre-
cisely functions to modulate expression.
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